Lithium Americas Corp vs Liquidia Corporation Common Stock — how do they compare? Lithium Americas Corp trades at $2.11 (market cap $758.34M), while Liquidia Corporation Common Stock trades at $34.2 (market cap $3.04B). The key difference: Liquidia Corporation Common Stock is far larger — about 4× Lithium Americas Corp's market cap, and Liquidia Corporation Common Stock is trading nearer its 52-week high, Lithium Americas Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lithium Americas Corp for 27 Days and Liquidia Corporation Common Stock for 0 Days on average.
| LAC | LQDA | |
|---|---|---|
Market Cap | $758.34M | $3.04B |
Volume | 10,089,473 | 21,111,778 |
Sector | Basic Materials | Health |
52-Week High | $9.44 | $91.03 |
52-Week Low | $2.07 | $22.02 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | $1.09B | $2.94B |
Signals from Pluang's Aura AI — not financial advice
Lithium Americas (LAC) trades at $2.20, down 2.22% with bearish technical signals but positive analyst sentiment. The company shows negative profitability metrics with ROE at -9.56% and net income of -$122.09M for 2025, though it has beaten earnings expectations in recent quarters. Strong financing activity ($1.14B in 2025) supports Thacker Pass development, a key growth catalyst.
LAC presents a high-risk, high-reward opportunity with analyst consensus price target of $4.00 (82% upside). While current fundamentals are weak due to pre-revenue phase, successful execution at Thacker Pass could drive significant revaluation. Key risks include lithium price volatility, project execution challenges, and continued cash burn during development.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →